APM
PRME icon

Avidity Partners Management’s Prime Medicine PRME Stock Holding History

Avidity Partners Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-694,000
Closed -$2.69M – 79
2024
Q3 		$2.69M Hold
694,000
– – 0.14% 73
2024
Q2 		$3.57M Sell
694,000
-1,296,000
-65% -$7.86M 0.15% 77
2024
Q1 		$13.9M Buy
+1,990,000
New +$15.1M 0.45% 61

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Avidity Partners Management's PRME Position: Q4 2024 in Review

Avidity Partners Management sold out of Prime Medicine (PRME) in Q4 2024, closing a stake of 694,000 shares — an estimated $2.69M sold.

Avidity Partners Management first reported a position in PRME in Q1 2024 and held it in 3 quarters. The position peaked at $13.9M in Q1 2024. 132 funds tracked by Wall St. Rank hold PRME as of Q4 2024.

  • Avidity Partners Management reported no remaining Prime Medicine position as of Q4 2024 after selling out during the quarter.
  • Avidity Partners Management sold 694,000 Prime Medicine shares in Q4 2024, an estimated $2.69M.
  • Avidity Partners Management first reported a position in Prime Medicine in Q1 2024 and held it in 3 quarters.
  • Avidity Partners Management's Prime Medicine position peaked at $13.9M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.